RETROSPECTIVE STUDY: L-DOPA WAS PROTECTIVE AGAINST WET AMD
Exogenous L-DOPA appeared to protect against the development of wet age-related macular degeneration (AMD) in multiple cohorts of patients, according to a retrospective study published in the American Journal of Medicine.1
Researchers analyzed medical records to compare the incidence of AMD in patients taking L-DOPA and those not taking L-DOPA. Three cohorts of patients were analyzed: two separate cohorts from the Marshfield Clinic in Wisconsin (n = 17 000 and n = 20 000) and one from the Truven MarketScan databases (n = 87 million).
For patients not taking L-DOPA, the average age of AMD diagnosis was approximately 71.3 years in all three groups. This was a significantly earlier onset than patients taking L-DOPA, who were diagnosed with AMD at an average age of 79.4 years.
1. Brilliant MH, Viziri K, Connor TB, et al. Mining retrospective data for virtual prospective drug repurposing: L-DOPA and age-related macular degeneration [published online ahead of print October 30, 2015]. Am J Med.